Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study | BMC Cancer | Full Text

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study | BMC Cancer | Full Text

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study

Gemcitabine/erlotinib treatment offers limited benefit in unselected patients with pancreatic ductal adenocarcinoma (PDAC). Development of skin rash has been associated with favorable outcomes in patients trea...

Authors:C. Benedikt Westphalen, Tobias Kukiolka, Benjamin Garlipp, Lars Hahn, Martin Fuchs, Peter Malfertheiner, Marcel Reiser, Fabian Kütting, Volker Heinemann, Andreas Beringer and Dirk T. Waldschmidt

Citation:BMC Cancer 2020 20:155

Content type:Research article

Published on: 24 February 2020

• ViewFull Text
 
• ViewPDF